|Former Common name||Atg13 KO|
|H-2 Haplotype||No Data|
|Background strain||No Data|
|Strain development||Developed by Noboru Mizushima, Graduate School and Faculty of Medicine, The University of Tokyo. With the CRISPR/Cas9, a frameshift mutation was introduced into exon 5 of the Atg13 gene. C57BL/6 genetic background.|
|Strain description||Atg13 knockout mice. Homozygous mutants are lethal at embryonic day 17, showing myocardial growth defects.|
|Health Report||No Data|
|Symbol name||autophagy related 13|
|Common name||No Data|
|Symbol description||No Data|
|Research applications||No Data|
|Specific Term and Conditions||The following terms and conditions will be requested by the DEPOSITOR.
Prior to requesting the BIOLOGICAL RESOURCE, the RECIPIENT must obtain approval from the DEPOSITOR using the Approval Form.
In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested.
Mol. Cell Biol. 36, 585-595 (2015).
In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.
BIOLOGICAL RESOURCE is limited to for academic research in non-profit organization. Any use of the BIOLOGICAL RESOURCE for profit purposes by a non-profit organization or any use of the BIOLOGICAL RESOURCE by a profit organization requires a separate license from the DEPOSITOR prior to distribution. The RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE.
|2||Genotyping protocol <PCR>|
|Depositor||Mizushima, Noboru (The University of Tokyo, Graduate School of Medicine)|
|Strain Status /